Journal
ONCOTARGETS AND THERAPY
Volume 10, Issue -, Pages 1767-1776Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S129449
Keywords
STAT3; EGFR; erlotinib; niclosamide; colon cancer
Categories
Funding
- National Natural Science Fund of China [21472142]
- Zhejiang Provincial Natural Science Fund [LY16H160052, LY17H160050, LY17H160055]
- Medical Scientific Research Fund of Zhejiang Province [2017192276]
- Wenzhou Science and Technology Project [Y20160052]
Ask authors/readers for more resources
Niclosamide, an anthelmintic drug approved by the US Food and Drug Administration against cestodes, is used to treat tapeworm infection. In this study, we show that niclosamide can potentially inhibit signal transducer and activator of transcription 3 (STAT3) in colon cancer cell lines. Combined inhibition of epidermal growth factor receptor and STAT3 by erlotinib and niclosamide synergistically induces apoptosis and antiproliferation in colon cancer cell lines. Our findings suggest that erlotinib and niclosamide combination provides an effective therapeutic approach to improving the prognosis of colon cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available